AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion in cash, adding two late-stage immunology assets to its pipeline while holding its full-year earnings guidance steady. The company reaffirmed its 2026 adjusted diluted EPS range of $13.87 to $14.07, absorbing a $0.14 per share dilutive impact from the deal in the current year.
AbbVie paid $135.11 per share for Apogee’s outstanding common stock. The company expects the acquisition to reduce 2026 adjusted diluted EPS by $0.14 and 2027 EPS by approximately $0.46, with accretion beginning in 2032. The 2026 guidance already reflects $0.58 per share in acquired in-process research and development (IPR&D) and milestone expenses incurred through the second quarter. AbbVie also reaffirmed its third-quarter 2026 adjusted diluted EPS guidance range of $3.84 to $3.88.
What it means
The reaffirmed guidance signals that AbbVie’s core business remains on track despite the $10.9 billion outlay. The company absorbed Apogee’s near-term earnings drag without cutting its full-year outlook, suggesting either that underlying operational performance is tracking ahead of prior expectations or that management had already modeled this acquisition into its guidance. The $0.14 dilutive impact for 2026 and $0.46 for 2027 are material but front-loaded; the company projects accretion by 2032, a six-year payoff window typical for early-stage pipeline acquisitions.
Apogee’s lead asset, zumilokibart, achieved clinically significant results in Phase 2 for atopic dermatitis, with approximately two-thirds of patients reaching significant skin clearance at 16 weeks. The molecule supports quarterly or twice-yearly dosing regimens. APG273, a combination therapy targeting both IL-13 and TSLP, is in earlier development for asthma. Both programs address large markets with existing competition, but the extended half-life and dosing convenience represent potential differentiation if clinical data hold through later trials.
The open question the filing leaves unresolved is whether Apogee’s Phase 2 efficacy translates to Phase 3 and regulatory success. Positive interim results in early-stage trials do not predict outcomes in larger, longer studies. The company explicitly notes that acquired IPR&D and milestone expenses “cannot be reliably forecasted” beyond the second quarter, meaning material clinical or regulatory setbacks could alter 2026 results materially.
What to watch
AbbVie’s third-quarter earnings report, due in late October 2026, will show whether the $0.14 dilutive impact materializes as guided and whether any additional IPR&D charges emerge. Phase 3 initiation or enrollment data for zumilokibart in atopic dermatitis will be the earliest clinical milestone signaling whether the asset is advancing on schedule. Any material delay or safety signal in either program would force a guidance revision and reset the accretion timeline.
Source: the company’s 8-K filed 2026-09-03 with the SEC.
For the standing yardsticks on Abbvie: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Abbvie.
